Iksuda Therapeutics, the developer of a new generation of antibody drug conjugates (ADCs) with raised therapeutic index, today announced that it has expanded its research collaboration and License Agreement with LegoChem Biosciences, Inc.to explore additional ADC programmes which leverage LCB’s proprietary ADC platform technology.
- Read more about LegoChem Biosciences and Iksuda Therapeutics expand License Agreement for development of antibody-drug conjugates
- Log in or register to post comments
source https://www.pharmatutor.org/pharma-news/2021/legochem-biosciences-and-iksuda-therapeutics-expand-license-agreement-for-development-of-antibody-drug-conjugates
No comments:
Post a Comment